Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Invasive fungal infections are an important cause of morbidity and mortality in critically ill and immunocompromised patients. Amphotericin B has remained the gold standard treatment for systemic fungal infections. The primary obstacle to amphotericin B therapy is its poor solubility and dose-related toxicities, especially renal impairment. As a result, newer lipid-based formulations of amphotericin B have been developed. This monograph compares available phamacokinetic, efficacy, and safety data for the 3 lipid-based formulations of amphotericin B, with reference to various patient populations. Potential causes of infusion-related reactions are described, and a premedication algorithm for the prevention of infusion-related reactions is developed.
Bellmann
Romuald
R
Division of General Internal Medicine Intensive Care Unit and Inflammation Innsbruck Medical School Department of Internal Medicine, Innsbruck, Austria
Cleary
John D
JD
Sterba
Jaroslav
J
D000666:Amphotericin B / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B